✦ LIBER ✦

The treatment of advanced ovarian cancer with adriamycin/ cisplatin alternating with etoposide/cisplatin

✍ Scribed by P.R. Dottino; R.A. Segna; C.J. Cohen

Book ID: 119054308
Publisher: Elsevier Science
Year: 1992
Tongue: English
Weight: 146 KB
Volume: 45
Category: Article
ISSN: 0090-8258
DOI: 10.1016/0090-8258(92)90579-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

First line combination chemotherapy with

First line combination chemotherapy with cisplatin and etoposide in advanced ovarian cancer

✍ Athanassiou, AE; Bafaloukos, D; Pectasides, D; Dimitriadis, M; Varthalitis, I; B 📂 Article 📅 1989 🏛 Nature Publishing Group 🌐 English ⚖ 618 KB

Long-term results of a randomized trial

Long-term results of a randomized trial comparing cisplatin with cisplatin and cyclophosphamide with cisplatin, cyclophosphamide, and adriamycin in advanced ovarian cancer

📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 325 KB

Treatment of advanced epithelial ovarian

Treatment of advanced epithelial ovarian cancer with cisplatin and cyclophosphamide

✍ David M. Gershenson; J.Taylor Wharton; Larry J. Copeland; C.Allen Stringer; Crei 📂 Article 📅 1989 🏛 Elsevier Science 🌐 English ⚖ 670 KB

Neoadjuvant chemotherapy with cisplatin

Neoadjuvant chemotherapy with cisplatin (CDDP)/adriamycin/ cyclophosphamide (CPM):(PAC) in advanced ovarian cancer

✍ Y. Terashima; M. Hirabayashi; H. Sasaki; K. Ochiai; M. Yakushiji 📂 Article 📅 1989 🏛 Elsevier Science 🌐 English ⚖ 167 KB

Treatment of advanced ovarian cancer wit

Treatment of advanced ovarian cancer with cisplatin, adriamycin, and cyclophosphamide: Effect of treatment and incidence of intracranial metastases

✍ G. Thomas Budd; Kenneth D. Webster; Ronald R. Reimer; Pierre Martimbeau; Robert 📂 Article 📅 1983 🏛 John Wiley and Sons 🌐 English ⚖ 324 KB

A retrospective analysis of 42 patients with stage 111, IV, or recurrcnt epithelial ovarian carcinoma treated with monthly cisplatin, Adriamycin, and cyclophosphamide (PAC) was made. Of 36 patients with measurable disease, 18 (50%) achieved a clinical complete response (CR) and 12 (33%) achieved a p

RANDOMISED COMPARISON OF CISPLATIN WITH

RANDOMISED COMPARISON OF CISPLATIN WITH CYCLOPHOSPHAMIDE/CISPLATIN AND WITH CYCLOPHOSPHAMIDE/DOXORUBICIN/ CISPLATIN IN ADVANCED OVARIAN CANCER

✍ Ginecologia, ; Interegionale, Gruppo; Oncologico, Cooperativo 📂 Article 📅 1987 🏛 The Lancet 🌐 English ⚖ 965 KB